HIV 1 News and Research

RSS

Fighting malaria in 2021: Where are we now and where are we going?

In support of World Malaria Day, News-Medical spoke to Dr. Laurence Slutsker, an internationally recognized expert in malaria, about fighting this disease in 2021.

26 Apr 2021

Disruptions to essential health services due to COVID-19 pandemic persist in 90% of countries

The second round of a World Health Organization "pulse survey" reveals that over one year into the COVID-19 pandemic, substantial disruptions persist, with about 90% of countries still reporting one or more disruptions to essential health services, marking no substantial global change since the first survey conducted in the summer of 2020.

23 Apr 2021

Only one vaccine is OK for older teens. It’s also the hardest to manage in rural America.

As states expand covid-19 vaccine eligibility to allow shots for 16- and 17-year-olds, teens in rural America may have trouble getting them.

23 Apr 2021

Celastrol shows potential anti-SARS-CoV-2 activity

A new study published on the bioRxiv* preprint server focuses on the in-silico predictions to repurpose existing drug compounds, that may have the ability to reverse the SARS-CoV-2 gene expression induced in host cells.

23 Apr 2021

New Phase 3 trial of therapeutics begins enrolling severely ill hospitalized COVID-19 patients

A new Phase 3 trial to test the safety and efficacy of therapeutics for COVID-19 has begun enrolling patients hospitalized with life-threatening cases of COVID-19, including those with acute respiratory failure.

22 Apr 2021

Patients with high HIV risk are aware of preventative pill, but few are using it

Cisgender sexual minority men and transgender women are aware of pre-exposure prophylaxis (PrEP), a daily pill for HIV-negative people to prevent HIV infection, but few are currently taking it, according to researchers at Rutgers.

22 Apr 2021

Strides against HIV/AIDS falter, especially in the South, as nation battles COVID

Facing a yearlong siege from the coronavirus, the defenses in another, older war are faltering.

21 Apr 2021

Characterization of lab-produced neutralizing antibodies targeting SARS-CoV-2

A new study led by Hans-Martin Jäck of the Friedrich-Alexander University Erlangen-Nuremberg in Germany engineered clusters of neutralizing monoclonal antibodies using a transgenic mouse model. A unique characteristic for the antibodies was the different ways it bound to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the overall reduction in the viral spread for human ACE2.

21 Apr 2021

Widely available HIV testing and treatment services increase life expectancy

Life expectancy among adults living with HIV receiving antiretroviral therapy (ART) in Latin America and the Caribbean has increased significantly since HIV testing and treatment services became more widely available, according to research published today in The Lancet HIV journal.

21 Apr 2021

SARS-CoV-2-associated ssRNAs trigger inflammation and immunity via toll-like receptors

Severe COVID-19 causes sepsis-like manifestations, intense lung injury, and multi-organ failure, all associated with the overproduction of pro-inflammatory cytokines. This "cytokine storm" directly correlates with poor prognosis in this subgroup of patients.

21 Apr 2021

Chronic SARS-CoV-2 infections favor viral adaptation, says study

A new study offers a look at how to keep these hopes alive in the current context of highly infectious variants, which often display immune escape mutations.

20 Apr 2021

Can an immunosuppressive cancer drug promote SARS-CoV-2 entry into host cells?

A new study shows that rapamycin, an immunosuppressive drug used in some cancers, and its analogs, may have an undesirable effect on viral entry into the host cells. This finding could inform their use to treat symptomatic COVID-19.

20 Apr 2021

Despite global efforts, allocation and distribution of COVID-19 vaccines are not equitable

Ensuring COVID-19 vaccine access for refugee and displaced populations, and addressing health inequities, is vital for an effective pandemic response.

20 Apr 2021

Could a tuna-derived protein inhibit SARS-CoV-2?

A recent study in the journal Food Chemistry draws attention to the need for finding nutritional supplements with potential SARS-CoV-2 inhibition effects in the wake of the COVID-19 pandemic.

19 Apr 2021

Benefits of continuing HIV services outweigh the potential harm of COVID-19 transmission

UNAIDS and WHO have supported mathematical modelling to establish the benefits of continuing HIV services compared to the potential harm of additional COVID-19 transmission.

19 Apr 2021

WHO calls for equitable treatment access and health services to everyone affected by Chagas disease

Today on World Chagas Disease Day, the World Health Organization has called for comprehensive and equitable access to health care and services to everyone affected by Chagas disease.

17 Apr 2021

Curcumin nanosystems could be powerful COVID-19 therapeutics

With new variants of SARS-CoV-2 emerging, the COVID-19 pandemic is far from over. While the global vaccine rollout has moved at an impressive speed, the search for new safe, effective, and targeted therapies is still on. Now, a new study reviews the potential for curcumin, a natural alkaloid derived from turmeric, and nanosystems to treat COVID-19.

16 Apr 2021

Repurposing an existing, cheap drug into long-acting injectable therapy to treat Covid-19

Researchers from the University of Liverpool have shown the potential of repurposing an existing and cheap drug into a long-acting injectable therapy that could be used to treat Covid-19.

16 Apr 2021

SARS-CoV-2 mutations impact T-cell recognition of virus

A new research paper posted to the bioRxiv preprint server deals with the impact of these mutations on adaptive cellular immunity.

14 Apr 2021

A new polymersome-based SARS-CoV-2 nanovaccine elicits robust immunity

As newer vaccines are being developed to combat the ongoing pandemic of coronavirus disease 2019 (COVID-19), targeting the pathogen, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a new preprint research paper posted to the bioRxiv server describes a new subunit nanovaccine that appears to have robust immunogenicity and neutralizing activity.

14 Apr 2021

HIV 1 News and Research

Fighting malaria in 2021: Where are we now and where are we going?

Disruptions to essential health services due to COVID-19 pandemic persist in 90% of countries

Only one vaccine is OK for older teens. It’s also the hardest to manage in rural America.

Celastrol shows potential anti-SARS-CoV-2 activity

New Phase 3 trial of therapeutics begins enrolling severely ill hospitalized COVID-19 patients

Patients with high HIV risk are aware of preventative pill, but few are using it

Strides against HIV/AIDS falter, especially in the South, as nation battles COVID

Characterization of lab-produced neutralizing antibodies targeting SARS-CoV-2

Widely available HIV testing and treatment services increase life expectancy

SARS-CoV-2-associated ssRNAs trigger inflammation and immunity via toll-like receptors

Chronic SARS-CoV-2 infections favor viral adaptation, says study

Can an immunosuppressive cancer drug promote SARS-CoV-2 entry into host cells?

Despite global efforts, allocation and distribution of COVID-19 vaccines are not equitable

Could a tuna-derived protein inhibit SARS-CoV-2?

Benefits of continuing HIV services outweigh the potential harm of COVID-19 transmission

WHO calls for equitable treatment access and health services to everyone affected by Chagas disease

Curcumin nanosystems could be powerful COVID-19 therapeutics

Repurposing an existing, cheap drug into long-acting injectable therapy to treat Covid-19

SARS-CoV-2 mutations impact T-cell recognition of virus

A new polymersome-based SARS-CoV-2 nanovaccine elicits robust immunity

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News